LAD328 Phase 2 Proof-of-Concept Trial for Moderate-to-Severe Hidradenitis Suppurativa
ClinicalTrials.gov Studies
Summary
The NIH ClinicalTrials.gov registry has published a new Phase 2 proof-of-concept study (NCT07547813) for LAD328 in adults with moderate-to-severe Hidradenitis Suppurativa. The study will evaluate LAD328 compared to placebo and assess safety, tolerability, pharmacokinetic, and immunogenicity parameters. The trial was registered with a start date of April 23, 2026, and lists LAD328 and placebo as the two interventions under investigation. Sponsors, clinical investigators, and patients interested in HS research can locate the study via its NCT identifier for further details.
“The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
The NIH ClinicalTrials.gov registry has added a new Phase 2 clinical trial registration for LAD328 (NCT07547813), a proof-of-concept study evaluating the investigational drug in adults with moderate-to-severe Hidradenitis Suppurativa. The study design includes LAD328 and placebo as interventions, with primary endpoints assessing comparative efficacy, safety, tolerability, pharmacokinetics, and immunogenicity. No enrollment count or specific completion date is listed in the registration record.
For pharmaceutical sponsors, clinical research organizations, and investigators active in inflammatory skin disease drug development, this registration signals the advancement of LAD328 into Phase 2 evaluation. Monitoring ClinicalTrials.gov for protocol details, enrollment status updates, and results postings will be relevant for competitive intelligence and patient-referral purposes.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
Phase 2 NCT07547813 Kind: PHASE2 Apr 23, 2026
Abstract
The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.
Conditions: Hidradenitis Suppurativa
Interventions: LAD328, Placebo
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.